-- NDI-101150 monotherapy achieved 18% objective response rate in heavily pretreated renal cell carcinoma (RCC) patients with prior exposure to checkpoint inhibitors -- -- Clinical benefit rate of 29% ...
Additionally, when combined with immune checkpoint inhibitors, NP-G2-044 has shown potential to reinvigorate anti-tumor immune responses. Novita's multicenter Phase 2 clinical trial, titled "NP-G2-044 ...
Designation encompasses treatment of pancreatic cancer, including use in combination with immune checkpoint inhibitors NEW YORK, Jan. 12, 2026 /PRNewswire/ -- Novita Pharmaceuticals, Inc. ("Novita"), ...
Research scientists found that a 'one-two punch' of combining the immunosuppressive drug ruxolitinib with existing checkpoint inhibitor therapies may be a more effective way to fight some cancers, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results